Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Special Report A Fresh IPO That Long-Term Investors Shouldn't IgnoreBy Jordan Chussler. Article Published: 1/14/2026. 
Key Points - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is a good time to revisit an initial public offering (IPO) calendar. Almost every week, companies go public, and a handful of them can offer considerable short-term upside potential. Of course, IPOs also carry substantial downside risk. But even conservative investors should not dismiss every recent listing—some newly public stocks may justify a place in buy-and-hold portfolios. One biotechnology company in the healthcare sector that just went public may be worth a closer look. Last Year's IPO Success Stories Last year shows why some IPOs can reward longer-term investors even if they look speculative at first. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since then. Short-term speculators may have benefited even more—the stock surged nearly 359% within its first 30 days on the Nasdaq—but investors who held on are still enjoying strong returns. Others, such as Medline (NASDAQ: MDLN), refute the notion that IPOs are only for risky startups. The medical products and services provider, which debuted publicly in December 2025, was founded in 1966 and already has a market cap above $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD)—famous for its bacon—waited 89 years before its IPO. Since going public in January 2025, the stock is up nearly 5% and has also rewarded shareholders with a dividend that currently yields 4.44% (about $1 per share annually), making it an immediate consideration for income investors. After its IPO, with shares beginning to trade on Jan. 9, Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals, is hoping for a similar outcome in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals—a subset of nuclear medicine that uses radioactive drugs for both diagnostics and treatment of diseases including cancer, heart disease and neurological conditions. Radiopharmaceuticals combine radioactive isotopes with a targeting module that seeks out particular cells (for example, cancer cells) to deliver localized doses of radiation. That targeted approach can reduce harm to healthy tissue compared with conventional radiology treatments. According to industry consultancy Grand View Research, the global nuclear medicine market, estimated at nearly $18 billion in 2024, is forecast to reach almost $35 billion by 2030—implying a compound annual growth rate of about 10.16%. Grand View Research also notes that North America accounts for nearly 43% of the global nuclear medicine market, with the United States the dominant regional player—an important point for Boston-based Aktis Oncology. Aktis Oncology's Clinical-Stage Business Wall Street expects biotech IPOs to rebound in 2026 after funding and policy shifts slowed healthcare listings in 2025. Aktis Oncology, which debuted on the Nasdaq on Jan. 9 as the first biotech IPO of 2026, raised $318 million in its offering and now has a market cap of about $3.34 billion—one of the larger recent raises for a biotech IPO. According to the company's prospectus, the executive team includes drug development, approval and commercialization veterans, and members of management have participated in bringing 14 currently FDA-approved products to market. At a product level, Aktis develops targeted alpha radiopharmaceuticals, a class of precision cancer drugs that uses proprietary technology to target solid tumors while minimizing exposure to healthy tissue. Aktis Oncology's Eli Lilly Connection Aktis is a clinical-stage, pre-revenue company, but that did not prevent it from attracting major strategic investors. Its IPO was anchored by Eli Lilly (NYSE: LLY). According to Reuters, Eli Lilly purchased $100 million of AKTS shares in the offering. That investment builds on a 2024 collaboration between the companies to develop tumor-targeting radiopharmaceuticals. As part of that relationship, Eli Lilly committed $60 million in cash and an equity investment to Aktis, with potential milestone payments that could exceed $1 billion. The significance of Lilly's backing should not be understated. Eli Lilly, with a market cap near $1.01 trillion, is the largest Big Pharma company by market capitalization. The company's net income rose nearly 109% year-over-year from 2023 to 2024, and that momentum may continue when Eli Lilly reports Q4 and full-year 2025 financials on Feb. 5. Between its equity stake and the $100 million of AKTS shares it purchased, the maker of Zepbound now has a sizable financial interest in the biotech startup's future success.
| 
